Canopy Growth Corp vs GameStop Corp. — how do they compare? Canopy Growth Corp trades at $1.03 (market cap $421.10M), while GameStop Corp. trades at $18.53 (market cap $8.44B). The key difference: GameStop Corp. is far larger — about 20× Canopy Growth Corp's market cap, and Canopy Growth Corp is trading nearer its 52-week high, GameStop Corp. nearer its low. Which is the better fit depends on your goals.
| CGC | GME | |
|---|---|---|
Market Cap | $421.10M | $8.44B |
Sector | Health | Consumer Cyclical |
52-Week High | $1.92 | $27.69 |
52-Week Low | $0.86 | $18.79 |
Enterprise Value | $378.55M | $4.42B |
Signals from Pluang's Aura AI — not financial advice
Canopy Growth (CGC) trades at $1.025, up 7.66% with bullish technical signals. The company shows improving fundamentals with Q1 2027 revenue growth of 13% and narrowing losses. Recent acquisitions and cost-cutting initiatives support expansion in medical and European cannabis markets. The stock trades below book value (P/B 0.86) while maintaining a P/S ratio of 1.71.
CGC presents a high-risk turnaround opportunity with improving balance sheet metrics and positive revenue momentum. However, persistent negative earnings and cash flow challenges require careful monitoring. Analyst sentiment remains divided with 33% buy ratings, reflecting the speculative nature of cannabis sector investments amid ongoing regulatory uncertainty.
GME trades at $18.605, down 0.98% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.30 beating expectations of $0.16. Revenue for 2025 was $3.82B, with net income of $131.3M and a profit margin of 3.43%. Recent news highlights a potential shift from a $56B eBay takeover bid to a partnership, as reported by Bloomberg on August 10, 2026.
The outlook is mixed: strong profitability improvements and debt reduction support upside, but analyst consensus is cautious with only 16.67% buy ratings. Key risks include execution of strategic partnerships, competitive pressures in retail, and shareholder dilution from recent debt-for-stock swaps. The stock's valuation appears reasonable with a P/E of 14.04, but sentiment remains divided.
Trailing returns across standard periods
Latest headlines on both assets
Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Tweed, Spectrum Therapeutics, and CraftGrow. Although it primarily operates in Canada, Canopy has distribution and production licenses in more than a dozen countries to drive expansion in global medical cannabis and also holds an option to acquire Acreage Holdings upon U.S. federal cannabis legalization.
Read more on CGC →Global Market Group Ltd. operates an Internet website that connects Chinese manufacturers with international buyers. The Company's customers can post company profiles and product information in standardized formats; post product listings; and trade leads.
Read more on GME →